摘要
中国心血管病负担日渐加重,已成为重大的公共卫生问题,防治心血管病刻不容缓。对于中西医并行的中国医疗现实来说,可以考虑中医药的服务能力。血栓心脉宁片是一种临床常用于缺血性中风恢复期、冠心病心绞痛治疗的中成药。该研究基于2013年中国医疗保险研究会全国城镇基本医疗保险参保住院患者数据,评估使用血栓心脉宁片治疗脑梗死和冠心病住院患者治疗费用、明细构成情况。同时,探析使用血栓心脉宁片患者疾病负担和直接医疗费用与基础西药组和对照中成药组的差异。结果显示,脑梗死与冠心病患者使用3组药物的人群中,血栓心脉宁组因各种病因导致的住院率(44.4%,29.6%)和因疾病导致的住院率(20.8%,5.2%)均为最低(P均<0.01),对照中成药组的半年内住院次数均为最高(P均<0.01)。脑梗死患者中,基础西药组、血栓心脉宁组和对照中成药组的年人均门诊总费用的中位数为7 476.8,7 601.8,15 650.1元(P<0.01),年人均住院总费用中位数为11 620.2,14 988.9,13 325.6元(P=0.058);冠心病患者中,3组相应年人均门诊总费用为6 831.4,10 228.6,13 132.4元(P<0.01),年人均住院总费用为13 354.7,14 911.5,15 725.3元(P=0.134)。结果表明,脑梗死和冠心病患者中使用血栓心脉宁组的住院率较低,有益于医院床位的周转,使得医院医疗资源可以被充分利用,且年人均门诊总费用均低于对照中成药组,利于降低疾病负担。
The increasing burden of cardiovascular disease in China has become a major public health problem, and the prevention and treatment of cardiovascular disease is in urgent need. For the reality of integrated Chinese and Western medicine in the Chinese health care system, we can consider the service ability of traditional Chinese medicine. Xueshuan Xinmaining Tablet is a kind of Chinese patent medicine commonly used in the treatment of recovery stage of ischemic stroke and angina pectoris of coronary heart disease. Based on the data of hospitalized patients covered by national urban basic medical insurance of China Medical Insurance Research Association in 2013, this study evaluated the treatment cost and detailed composition of the cost for the patients with cerebral infarction and coronary heart disease treated by Xueshuan Xinmaining Tablets. At the same time, the differences in disease burden and direct medical expenses among Xueshuan Xinmaining Tablets group, Western medicine group and another commonly used Chinese patent medicine group were analyzed. Among the three groups of patients with cerebral infarction and coronary heart disease, the hospitalization rates caused by various causes(44.4% and 29.6%) and diseases(20.8% and 5.2%) in Xueshuan Xinmaining Tablets group were the lowest(all P<0.01), and the number of hospitalization times in half a year was highest in the common Chinese patent medicine group(all P<0.01). In patients with cerebral infarction, the median annual total outpatient expenses were 7 476.8, 7 601.8, 15 650.1 yuan respectively in Western medicine group, Xueshuan Xinmaining Tablets group and the common Chinese patent medicine group(P<0.01), and the median hospitalization expenses were 11 620.2, 14 988.9, 13 325.6 yuan respectively(P=0.058). In patients with coronary heart disease, the total outpatient expenses of the three groups were 6 831.4, 10 228.6, 13 132.4 yuan respectively(P<0.01), and the total hospitalization expenses were 13 354.7, 14 911.5, 15 725.3 yuan respectively(P=0.134). Th
作者
胡晶
高双庆
王阶
李军
陈恒文
戴泽琦
廖星
HU Jing;GAO Shuang-qing;WANG Jie;LI Jun;CHEN Heng-wen;DAI Ze-qi;LIAO Xing(Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing Institute of Traditional Chinese Medicine,Beijing 100010,China;Center for Evidence-based Chinese Medicine,Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Beijing North Medicine Health Economy Research Center,Beijing 100021,China;Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2021年第9期2309-2316,共8页
China Journal of Chinese Materia Medica
基金
国家自然科学基金面上项目(81774159,81973694)
中国中医药循证中心业务研究室主任专项(2020YJSZX-2)。
关键词
血栓心脉宁片
脑梗死
冠心病
直接医疗费用
Xueshuan Xinmaining Tablets
cerebral infarction
coronary heart disease
direct medical cost
